Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 330-337

  Iwase, Yuko ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

antitumor activity; CPT 11; medullary thyroid carcinoma; octreotide; somatostatin receptor; targeting liposome

Indexed keywords

IRINOTECAN; LIPOSOME; MACROGOL; OCTREOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CAMPTOTHECIN; CELL PROLIFERATION; DRUG CARRIERS; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL AGENTS; HUMANS; LIPOSOMES; MICE; MICE, INBRED ICR; MICE, NUDE; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79953821130     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100380y     Document Type: Article

References (35)

1. Vitale, G.; Caraglia, M.; Ciccarelli, A.; Lupoli, G.; Abbruzzese, A.; Tagliaferri, P.; Lupoli, G. Current Approaches and Perspectives in the Therapy of Medullary Thyroid Carcinoma. Cancer 2001, 91, 1797-1808.
2. Cakir, M.; Grossman, A. B. Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies. Neuroendocrinolgy 2009, 90, 323-348.
3. Giuffrida, D.; Gharib, H. Current diagnosis and management of medullary thyroid carcinoma. Ann. Oncol. 1998, 9, 695-701.
4. Strock, C. J.; Park, J. I.; Rosen, D. M.; Ruggeri, B.; Denmeade, S. R.; Ball, D. W.; Nelkin, B. D. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91, 79-84.
5. Koga, K.; Hattori, Y.; Komori, M.; Narishima, R.; Yamasaki, M.; Hakoshima, M.; Fukui, T.; Maitani, Y. Cancer Sci. 2010, 101, 941-947.
6. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11,in the antitumor effect of CPT-11. Cancer Res. 1991, 51, 4187-4191.
7. Kawato, Y.; Furuta, T.; Aonuma, M.; Yasuoka, M.; Yokokura, T.; Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol. 1991, 28, 192-198.
8. Hsiang, Y. H.; Wu, H. Y.; Liu, L. F. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem. Pharmacol. 1988, 37, 1801-1802.
9. Hsiang, Y. H.; Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988, 48, 1722-1726.
10. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin. Cancer Res. 1989, 49, 5077-5082. (Pubitemid 19239347)
11. Ohno, R.; Okada, K.; Masaoka, T.; Kuramoto, A.; Arima, T.; Yoshida, Y.; Ariyoshi, H.; Ichimaru, M.; Sasaki, Y.; Oguro, M.; Ito, Y.; Morishima, Y.; Yokomaku, S.; Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 1990, 8, 1907-1912.
12. Grozinsky-Glasberg, S.; Shimon, I.; Korbonits, M.; Grossman, A. B. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr.-Relat. Cancer 2008, 15, 701-720.
13. Zatelli, M. C.; Tagliati, F.; Taylor, J. E.; Rossi, R.; Culler, M. D.; Uberti, E. C. Somatostatin Receptor Subtypes 2 and 5 Differentially Affect Proliferation in Vitro of the Human Medullary Thyroid Carcinoma Cell Line TT. J. Clin. Endocrinol. Metab. 2001, 86, 2161-2169.
14. Zatelli, M. C.; Tagliati, F.; Taylor, J. E.; Piccin, D.; Culler, M. D.; Uberti, E. C. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm. Metab. Res. 2002, 5, 229-233.
15. Mato, E.; Matias-Guiu, X.; Chico, A.; Webb, S. M.; Cabezas, R.; Berná, L.; Leiva, A. Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 1998, 83, 2417-2420.
16. Froidevaux, S.; Eberle, A. N. Somatostatin analogues and radiopeptides in cancer therapy. Biopolymers 2002, 66, 161-183. (Pubitemid 35285217)
17. Lemaire, M.; Azria, M.; Dannecker, R.; Marbach, P.; Schweitzer, A.; Maurer, G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab. Dispos. 1998, 17, 699-703.
18. Kutz, K.; Nüesch, E.; Rosenthaler, J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand. J. Gastroenterol. Suppl. 1986, 119, 65-72.
19. Bakker, W. H.; Krenning, E. P.; Breeman, W. A.; Kooij, P. P.; Koper, J. C.; Jong, M.; Lameris, J. S.; Visser, T. J.; Lamberts, S. W. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J. Nucl. Med. 1991, 32, 1184-1189.
20. Froidevaux, S.; Heppeler, A.; Eberle, A. N.; Meier, A. M.; Hausler, M.; Beglinger, C.; Behe, M.; Powell, P.; Macke, H. R. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1, 4, 7, 10- tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinolgy 2000, 141, 3304-3312.
21. Smith-Jones, P. M.; Stolz, B.; Albert, R.; Ruser, G.; Briner, U.; Macke, H. R.; Bruns, C. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumors. Nucl. Med. Biol. 1998, 25, 1981-1988.
22. Chang, C. C.; Liu, D. Z.; Lin, S. Y.; Liang, H. J.; Hou, W. C.; Huang, W. J.; Chang, C. H.; Ho, F. M.; Liang, Y. C. Liposome encapsulation reduces cantharidin toxicity. Food Chem. Toxicol. 2008, 46, 3116-3121.
23. Chen, C. H.; Liu, D. Z.; Fang, H. W.; Liang, H. J.; Yang, T. S.; Lin, S. Y. Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer. Biosci., Biotechnol., Biochem. 2008, 72, 1586-1594.
24. Hattori, Y.; Shi, L.; Ding, W.; Koga, K.; Kawano, K.; Hakoshima, M.; Maitani, Y. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J. Controlled Release 2009, 136, 30-37.
25. Su, J. C.; Tseng, C. L.; Chang, T. G.; Yu, W. J.; Wu., S. K. A synthetic method for peptide-PEG-lipid conjugates: Application of Octreotide-PEG-DSPE synthesis. Bioorg. Med. Chem. Let. 2008, 18, 4593-4596.
26. Yamada, A.; Taniguchi, Y.; Kawano, K.; Honda, T.; Hattori, Y.; Maitani, Y. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res. 2008, 14, 8161-8168.
27. Arai, H.; Suzuki, T.; Kaseda, C.; Ohyama, K.; Takayama, K. Bootstrap Re-sampling Technique to Evaluate the Optimal Formulation of Theophylline Tablets Predicted by Non-linear Response Surface Method Incorporating Multivariate Spline Interpolation. Chem. Pharm. Bull. 2007, 55, 586-593.
28. Ishida, O.; Maruyama, K.; Tanahashi, H.; Iwatsuru, M.; Sasaki, K.; Eriguchi, M.; Yanagie, H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 2001, 18, 1042-1048.
29. Stroh, T.; Jackson, A. C.; Farra, C. D.; Schonbrunn, A.; Vincent, J. P.; Beaudet, A. Receptor-mediated internalization of somatostatin in rat cortical and hippocampal neurons. Synapse 2000, 38, 177-186.
30. Huang, C. M.; Wu, Y. T.; Chen, S. T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 2000, 7, 453-461.
31. Barone, R.; Smissen, P. V. D.; Devuyst, O.; Beaujean, V.; Pauwels, S.; Courtoy, P. J.; Jamar, F. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int. 2005, 67, 969-976.
32. Modigliani, E.; Cohen, R.; Joannidis, S.; Siame-Mourot, C.; Guliana, J. M.; Charpentier, G.; Cassuto, D.; Pessayre, M. B.; Tabarin, A.; Roger, P. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin. Endocrinol. 1992, 36, 183-186.
33. Lupoli, G.; Cascone, E.; Arlotta, F.; Vitale, G.; Celentano, L.; Salvatore, M.; Lombardi, G. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1996, 78, 1114-1118. (Pubitemid 26284878)
34. Gabizon, A.; Shmeeda, H.; Horowitz, A. Z.; Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Delivery Rev. 2004, 56, 1177-1192.
35. Theodoropoulou, M.; Zhang, J.; Laupheimer, S.; Paez-Pereda, M.; Erneux, C.; Florio, T.; Pagotto, U.; Stalla, G. K. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006, 66, 1576-1582.